"Mount Sinai Patient, Clinical Researcher Discuss New Treatment for Eczema Approved by FDA"
An eczema patient in a Mount Sinai clinical trial and a Mount Sinai physician-scientist who led the trial discuss Dupixent® (dupilumab), the first biologic medicine approved by the U.S. Food and Drug Administration for the treatment of adults with moderate to severe atopic dermatitis. Learn more